Unnamed: 0,title,date,stock,sentiment
1122143.0,SCYNEXIS Q1 EPS $(0.070) Up From $(0.460) YoY,2020-05-11 09:02:00-04:00,SCYX,neutral
1122144.0,SCYNEXIS Highlights 6 Abstracts Published By ECCMID Related To Potential Clinical Utility Of Ibrexafungerp,2020-05-06 08:13:00-04:00,SCYX,neutral
1122145.0,"Aegis Capital Maintains Buy on SCYNEXIS, Raises Price Target to $4.5",2020-04-23 12:40:00-04:00,SCYX,neutral
1122146.0,20 Healthcare Stocks Moving In Thursday's Pre-Market Session,2020-04-23 07:31:00-04:00,SCYX,neutral
1122147.0,SCYNEXIS Shares To Resume Trade At 7:30 a.m. EDT,2020-04-21 07:11:00-04:00,SCYX,positive
1122148.0,SCYNEXIS Announces Ibrexafungerp  Achieved Statistically Significant Superiority Over Placebo For Primary And Key Secondary Study Endpoints,2020-04-21 07:03:00-04:00,SCYX,positive
1122149.0,"SCYNEXIS Shares Halted, News Pending",2020-04-21 07:01:00-04:00,SCYX,positive
1122150.0,"SCYNEXIS, Aspire Capital Report $20M Common Stock Purchase Deal",2020-04-13 08:54:00-04:00,SCYX,neutral
1122151.0,"The Week Ahead In Biotech: Urogen FDA Decision, Amarin, J&J Earnings And More COVID-19 Updates",2020-04-12 10:05:00-04:00,SCYX,neutral
1122152.0,"The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection",2020-03-19 07:37:00-04:00,SCYX,neutral
1122153.0,"The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Shipment, Regeneron Aims For 'Cocktail' COVID-19 Treatment",2020-03-17 08:48:00-04:00,SCYX,neutral
1122154.0,"The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings",2020-03-13 07:52:00-04:00,SCYX,negative
1122155.0,"SCYNEXIS Reports Preclinical Data On Ibrexafungerp, Azoles Against Aspergillus Presented At Advances Against Aspergillosis and Mucormycosis Conference",2020-03-05 08:12:00-05:00,SCYX,neutral
1122156.0,SCYNEXIS Completes Patient Enrollment Ahead Of ScheduleIn Second Pivotal Phase 3 Study Of Oral Ibrexafungerp For The Treatment Of Vulvovaginal Candidiasis,2020-02-13 08:16:00-05:00,SCYX,neutral
1122157.0,18 Drug Manufacturersâ€”Specialty & Generic Stocks Moving In Wednesday's Session,2020-01-22 13:28:00-05:00,SCYX,neutral
1122158.0,50 Healthcare Stocks Moving In Wednesday's Pre-Market Session,2020-01-08 08:31:00-05:00,SCYX,neutral
1122159.0,"SCYNEXIS Announces Results From Second Interim Analysis Of Ongoing Phase 3 FURI Study, Demonstrating Oral Ibrexafungerp's Ability To Treat Severe Fungal Infections In The Hospital Setting",2020-01-08 07:37:00-05:00,SCYX,positive
1122160.0,30 Healthcare Stocks Moving In Wednesday's Pre-Market Session,2019-12-18 08:11:00-05:00,SCYX,neutral
1122161.0,19 Healthcare Stocks Moving In Tuesday's Pre-Market Session,2019-12-17 07:57:00-05:00,SCYX,neutral
1122162.0,"Scynexis CEO Taglietti Buys 333,334 @ Avg Price: $0.45",2019-12-16 15:14:00-05:00,SCYX,neutral
1122163.0,41 Healthcare Stocks Moving In Tuesday's Pre-Market Session,2019-12-10 08:10:00-05:00,SCYX,neutral
1122164.0,"The Daily Biotech Pulse: ASH Meeting Wraps, Fast Track Designation For Equillium, Pfizer To Buy $3M In ContraFect Shares",2019-12-10 07:56:00-05:00,SCYX,positive
1122165.0,SCYNEXIS Q3 EPS $(0.14) Down From $0.01 YoY,2019-11-12 08:45:00-05:00,SCYX,neutral
1122166.0,"SCYNEXIS Shares Resume Trade, Up 21%",2019-11-07 08:32:00-05:00,SCYX,positive
1122167.0,SCYNEXIS Shares To Resume Trade At 8:30 a.m. EST,2019-11-07 08:05:00-05:00,SCYX,positive
1122168.0,"SCYNEXIS Says Second Phase 3 Study Of Ibrexafungerp On Track For Top-Line Results In Early Q2'20, Supporting NDA Submission In H2'20",2019-11-07 08:04:00-05:00,SCYX,positive
1122169.0,"SCYNEXIS Reports Ibrexafungerp For Vulvovaginal Candidiasis Achieved Highly Statistically Significant Superiority Over Placebo For Primary Endpoint, Was Generally Safe, Well Tolerated",2019-11-07 08:04:00-05:00,SCYX,positive
1122170.0,SCYNEXIS Shares Halted News Pending,2019-11-07 07:55:00-05:00,SCYX,positive
1122171.0,24 Healthcare Stocks Moving In Monday's Pre-Market Session,2019-11-04 08:13:00-05:00,SCYX,neutral
1122172.0,SCYNEXIS Announces Oral Presentation of Data From Ibrexafungerp Phase 2b DOVE Study At The 3rd ISIDOG Congress  Oct. 31-Nov. 1,2019-10-31 09:48:00-04:00,SCYX,neutral
1122173.0,"SCYNEXIS Reports Amendment To Protocol For Ongoing FURI Study Probing Safety, Efficacy Of Oral Ibrexafungerp As Salvage Treatment For Patients With Resistant, Refractory Severe Fungal Infections",2019-10-24 08:33:00-04:00,SCYX,positive
1122174.0,"SCYNEXIS Reports Non-Dilutive Funding Through New Jersey Economic Development Authority Net Operating Loss, R&D Tax Credits Program; Expects To Receive $3.3M In Cash By End Of 2019",2019-10-10 08:42:00-04:00,SCYX,positive
1122175.0,SCYNEXIS Completes Last-Patient/Last-Visit Ahead Of Schedule In First Phase 3 Study Of Oral Ibrexafungerp For Treatment Of Vulvovaginal Candidiasis,2019-09-18 08:31:00-04:00,SCYX,neutral
1122176.0,SCYNEXIS Announces Special Protocol Assessment (SPA) Agreement With FDA For Phase 3 Study Evaluating Oral Ibrexafungerp For Prevention Of Recurrent Vulvovaginal Candidiasis (VVC) (CANDLE Study),2019-07-24 08:10:00-04:00,SCYX,positive
1122177.0,SCYNEXIS Reports Completion Of Chronic Nonclinical Toxicology Studies Supporting Long-Term Administration Of Ibrexafungerp,2019-05-30 08:35:00-04:00,SCYX,positive
1122178.0,"SCYNEXIS Q1 EPS $(0.46) Misses $(0.2) Estimate, Sales $64K Miss $90K Estimate",2019-05-08 17:19:00-04:00,SCYX,negative
1122179.0,SCYNEXIS Mentioned In Chemotherapy Journal Article,2019-04-25 13:20:00-04:00,SCYX,neutral
1122180.0,"The Daily Biotech Pulse: J&J Earnings, FDA Nod For Medicinova, Proteon To Explore Strategic Alternatives",2019-04-16 08:10:00-04:00,SCYX,neutral
1122181.0,"The Week Ahead In Biotech: Conferences, Clinical Trial Readouts, Earnings And IPOs",2019-04-13 09:38:00-04:00,SCYX,neutral
1122182.0,SCYNEXIS shares are trading higher after the company commended the New York Times for reporting on Candida auris and the major global health issues caused by drug-resistant pathogens.,2019-04-08 09:34:00-04:00,SCYX,positive
1122183.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Readouts",2019-04-07 17:04:00-04:00,SCYX,neutral
1122184.0,SCYNEXIS Reports Its Ibrexafungerp Showed Favorable Clinical Activity In Resistance Fungal Infections In Data Presented At ECCMID,2019-04-03 08:31:00-04:00,SCYX,positive
1122185.0,SCYNEXIS S-3 Shows Registration For 13.008M Common Shares,2019-03-22 16:09:00-04:00,SCYX,positive
1122186.0,SCYNEXIS Provides Company Update,2019-03-14 16:40:00-04:00,SCYX,neutral
1122187.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Morning Of Fri., Feb. 1, 2019",2019-02-01 10:05:00-05:00,SCYX,positive
1122188.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Morning Of Thurs., Jan. 31, 2019",2019-01-31 09:26:00-05:00,SCYX,positive
1122189.0,SCYNEXIS shares are trading higher after a Phase 3 study of ibrexafungerp showed the drug demonstrated efficacy in 17 of 20 patients with fungal infections.,2019-01-31 08:28:00-05:00,SCYX,positive
1122190.0,SCYNEXIS shares are trading higher after a Phase 3 study of ibrexafungerp showed the drug demonstrated efficacy in 17 of 20 patients with fungal infections.,2019-01-30 17:19:00-05:00,SCYX,positive
1122191.0,SCYNEXIS Reports Interim Results From Phase 3 Open-Label FURI Study Showed Ibrexafungerp's Ability to Treat Refractory Fungal Infections and to Provide an Alternative to Long-Term IV Therapies,2019-01-30 16:39:00-05:00,SCYX,positive
1122192.0,Scynexis Shares Trade Higher As Traders Circulate Medical Journal Mentioning The Company,2019-01-29 12:29:00-05:00,SCYX,positive
1122193.0,"The Daily Biotech Pulse: Novavax Reports Positive Influenza Vaccine Trial Data, Flexion Warns Of Revenue Shortfall, Retrophin's New CEO",2019-01-04 07:59:00-05:00,SCYX,positive
1122194.0,"UPDATE: SCYNEXIS Reports 'Received non-dilutive state incentive cash benefit of $6.7 million; approximately $51 million cash balance as of January 3, 2019, sufficient to ensure full funding of the VANISH Phase 3 VVC trials past top-line data'",2019-01-03 16:09:00-05:00,SCYX,positive
1122195.0,"SCYNEXIS Offers Year-End Update, Outlines 2019 Plans",2019-01-03 16:08:00-05:00,SCYX,neutral
1122196.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials",2018-12-30 15:27:00-05:00,SCYX,neutral
1122197.0,The Week Ahead In Biotech: Focus Shifts To Year-End Clinical Trial Results,2018-12-23 10:37:00-05:00,SCYX,neutral
1122198.0,"The Daily Biotech Pulse: Puma Aces Late-Stage Trial, Chinese Cheer For FibroGen, J&J $5B Buyback Plan",2018-12-18 08:00:00-05:00,SCYX,positive
1122199.0,"The Daily Biotech Pulse: Axovant In-Licenses 2 Gene Therapies, Agile To Undertake Additional Study Of Contraceptive Patch",2018-12-14 07:47:00-05:00,SCYX,neutral
1122200.0,"The Daily Biotech Pulse: Vivus Extends Supply Deal With Sandoz, Applied Genetic Snaps Ties With Biogen",2018-12-13 07:56:00-05:00,SCYX,positive
1122201.0,"Stocks Which Set New 52-Week Low Yesterday, Tues., Dec. 11, 2018",2018-12-12 11:47:00-05:00,SCYX,negative
1122202.0,"The Daily Biotech Pulse: Legal Victory For Boston Scientific, Alder Gets New CFO, FDA Go-Ahead For BioXcel",2018-12-12 08:07:00-05:00,SCYX,positive
1122203.0,"Stocks Which Set New 52-Week Low Yesterday, Mon., Dec. 3, 2018",2018-12-04 09:21:00-05:00,SCYX,negative
1122204.0,"The Daily Biotech Pulse: ASH Presentations Take The Spotlight, Eiger Gets A New CFO",2018-12-04 07:59:00-05:00,SCYX,neutral
1122205.0,"Stocks Which Set New 52-Week Low The Last Trading Session, Wed., Nov. 21, 2018",2018-11-23 09:09:00-05:00,SCYX,negative
1122206.0,"The Daily Biotech Pulse: Mylan Recalls Blood Pressure Drug, Heat Biologics Offering, New Novelion CEO",2018-11-21 08:04:00-05:00,SCYX,negative
1122207.0,"Stocks Which Set New 52-Week Lows Fri., Nov. 16, 2018",2018-11-19 10:16:00-05:00,SCYX,negative
1122208.0,"Stocks Which Set New 52-Week Low Yesterday, Thurs., Nov. 16, 2018",2018-11-16 10:37:00-05:00,SCYX,negative
1122209.0,"The Daily Biotech Pulse: Mallinckrodt Faces FDA Panel, Reshape's Earnings, Vapotherm To Debut",2018-11-14 08:17:00-05:00,SCYX,neutral
1122210.0,"Scynexis Q3 EPS $0.01 Beats $(0.18) Estimate, Sales $64K Miss $70K Estimate",2018-11-13 09:11:00-05:00,SCYX,negative
1122211.0,"The Daily Biotech Pulse: Viking's Fatty Liver And Cholesterol Drug, Cyclacel Loss Narrows, Eton's Debut",2018-11-13 07:54:00-05:00,SCYX,negative
1122212.0,"The Daily Biotech Pulse: Illumina's Strong Q3, Celgene's Positive Cancer Drug Trial, Proteostasis Offering",2018-10-24 07:48:00-04:00,SCYX,positive
1122213.0,"Stocks Which Set New 52-Week Low Yesterday, October 22nd",2018-10-23 09:54:00-04:00,SCYX,negative
1122214.0,SCYNEXIS Reports Completion Of End-Of-Phase 2 Meeting With FDA; FDA Has Agreed To Co.'s Overall Design Of Phase 3 Vulvovaginal Candidiasis Program For Oral Ibrexafungerp,2018-10-23 09:04:00-04:00,SCYX,positive
1122215.0,UPDATE: SCYNEXIS Says Is On Target To Initiate Phase 3 Registration Program In Q4'18,2018-10-23 09:03:00-04:00,SCYX,neutral
1122216.0,SCYNEXIS Reports FDA Deal For Phase 3 Vulvovaginal Candidiasis Program For Oral Ibrexafungerp,2018-10-23 09:02:00-04:00,SCYX,neutral
1122217.0,"The Daily Biotech Pulse: Regulus Soars On Positive Pre-Clinical Data, Biogen Earnings, Proteostasis And Eiger to Offer Shares",2018-10-23 08:35:00-04:00,SCYX,positive
1122218.0,"SCYNEXIS, Inc. Announces First Patient Dosed In Phase 3 Open-label Study Evaluating Oral Ibrexafungerp In Candida auris Infections",2018-10-15 09:27:00-04:00,SCYX,neutral
1122219.0,Calyxt Names Dr. Yves J. Ribeill Interim CEO,2018-08-22 08:03:00-04:00,SCYX,neutral
1122220.0,"SCYNEXIS Q2 EPS $(0.23) Misses $(0.17) Estimate, Sales $64K Miss $70K Estimate",2018-08-09 16:21:00-04:00,SCYX,negative
1122221.0,SCYNEXIS Shars Up 24.9% After Hours Following Evidence Of Clinical Effectiveness Of Oral SCY-078 Shown In Phase 2b Study,2018-07-10 16:40:00-04:00,SCYX,neutral
1122222.0,UPDATE: Initiation Of Phase 3 Registration Program In VVC Planned For Q4 '18,2018-07-10 16:17:00-04:00,SCYX,neutral
1122223.0,SCYNEXIS Shares To Resume Trade At 4:35 p.m. EDT,2018-07-10 16:10:00-04:00,SCYX,positive
1122224.0,UPDATE: SCYNEXIS Says Results Of Phase 2b Oral SCY-078 Study 'confirm strong clinical activity of oral SCY-078 and suggest improved sustained benefit relative to the standard of care',2018-07-10 16:06:00-04:00,SCYX,positive
1122225.0,SCYNEXIS Reports Results From Phase 2b Dose-Finding Study Of Oral SCY-078 In Vulvovaginal Candidiasis: 'Clinically and mycologically effective and well-tolerated...identified for use in Phase 3 registration program',2018-07-10 16:06:00-04:00,SCYX,positive
1122226.0,Scynexis Shares Halted News Pending,2018-07-10 16:05:00-04:00,SCYX,positive
1122227.0,"Canaccord Genuity Assumes SCYNEXIS at Buy, Announces Price Target $4",2018-06-29 07:46:00-04:00,SCYX,neutral
1122228.0,UPDATE: SCYNEXIS Highlights 'SCY-078 has the potential to provide a safer treatment option for pregnant women experiencing fungal infections and for patients who may become pregnant while on antifungal therapy',2018-06-27 08:15:00-04:00,SCYX,positive
1122229.0,"SCYNEXIS Reports SCY-078 Showed 'no impact on fertility or early embryonic development in pre-clinical studies, a differentiator vs. current treatments'",2018-06-27 08:15:00-04:00,SCYX,negative
1122230.0,"Maxim Group Initiates Coverage On SCYNEXIS with Buy Rating, Announces $6 Price Target",2018-06-27 07:29:00-04:00,SCYX,neutral
1122231.0,"UPDATE: SCYNEXIS Says 'On track to report Phase 2b data in VVC by Jul. 2018, with Phase 3 trial initiation in Q4'18'",2018-06-06 08:31:00-04:00,SCYX,neutral
1122232.0,UPDATE: SCYNEXIS Says Results For SCY-078 'suggest potential clinical relevance of SCY-078 for patients with Type 2 diabetes with VVC',2018-06-06 08:31:00-04:00,SCYX,neutral
1122233.0,SCYNEXIS Reports Publication Of Phase 1 Study Results For SCY-078 In Journal Of Clinical Pharmacology: Showed 'low risk of interactions between SCY-078 and drugs metabolized by CYP enzymes',2018-06-06 08:31:00-04:00,SCYX,negative
1122234.0,45 Biggest Movers From Yesterday,2018-05-25 04:37:00-04:00,SCYX,neutral
1122235.0,42 Stocks Moving In Thursday's Mid-Day Session,2018-05-24 13:31:00-04:00,SCYX,neutral
1122236.0,"Benzinga's Top Upgrades, Downgrades For May 24, 2018",2018-05-24 09:40:00-04:00,SCYX,positive
1122237.0,"Ladenburg Thalmann Initiates Coverage On SCYNEXIS with Buy Rating, Announces $9 Price Target",2018-05-24 07:09:00-04:00,SCYX,neutral
1122238.0,"SCYNEXIS Q1 EPS $(0.12) Beats $(0.21) Estimate, Sales $64K Beat $60K Estimate",2018-05-08 16:23:00-04:00,SCYX,neutral
1122239.0,"Benzinga's Top Upgrades, Downgrades For May 7, 2018",2018-05-07 09:20:00-04:00,SCYX,positive
1122240.0,"H.C. Wainwright Assumes SCYNEXIS at Buy, Announces Price Target $5",2018-05-07 07:05:00-04:00,SCYX,neutral
1122241.0,SCYNEXIS Shares Up 4.2% After Co. Earlier Reported It Received FDA QIDP and Fast Track Designations For Its Oral SCY-078,2018-05-01 12:38:00-04:00,SCYX,positive
1122242.0,"SCYNEXIS Reports Oral SCY-078 Received FDA QIDP, Fast Track Designations For Treatment Of VVC, Prevention Of Recurrent VVC",2018-05-01 08:33:00-04:00,SCYX,neutral
1122243.0,"Benzinga's Daily Biotech Pulse: Catabasis Soars On Trial Results, Eloxx Listing, Biomarin Earnings",2018-04-26 08:07:00-04:00,SCYX,neutral
1122244.0,"Seaport Global Initiates Coverage On SCYNEXIS with Buy Rating, Announces $4.00 Price Target",2018-04-10 09:40:00-04:00,SCYX,neutral
1122245.0,"SCYNEXIS Reports FY17 EPS $(0.94) vs $(0.99) Est., Sales $257K vs $90K Est.",2018-03-13 16:29:00-04:00,SCYX,neutral
1122246.0,SCYNEXIS Prices Offering At $1.69/Share For Expected Gross Proceeds ~$30M,2018-03-06 09:27:00-05:00,SCYX,negative
1122247.0,"SCYNEXIS Shares Down 12% After Hours Following Launch Of Offering Of Common Shares, Warrants, No Amount Disclosed",2018-03-05 16:08:00-05:00,SCYX,positive
1122248.0,"SCYNEXIS Reports Launch Of Offering Of Common Shares, Warrants, No Amount Disclosed",2018-03-05 16:03:00-05:00,SCYX,neutral
1122249.0,UPDATE: SCYNEXIS Sees Phase 2 Trial In Invasive Aspergillosis Expected To Be Initiated In Q3'18,2018-02-01 08:35:00-05:00,SCYX,neutral
1122250.0,SCYNEXIS Reports New In Vivo Data Showing 'synergistic activity and improved outcomes of SCY-078 in combination with isavuconazole',2018-02-01 08:34:00-05:00,SCYX,positive
1122251.0,30 Stocks Moving In Friday's Mid-Day Session,2018-01-05 12:15:00-05:00,SCYX,neutral
1122252.0,"SCYNEXIS Reports Q3 EPS $(0.31) vs $(0.34) Est., Sales $64K vs $64K In Same Qtr. Last Year",2017-11-07 16:21:00-05:00,SCYX,neutral
1122253.0,"Guggenheim Initiates Coverage On SCYNEXIS with Buy Rating, Announces $6.00 Price Target",2017-10-24 09:18:00-04:00,SCYX,neutral
1122254.0,"SCYNEXIS Reports New Data On SCY-078 For Potential Treatment For Aspergillus, Candida Infections: 'In vivo and in vitro data show SCY-078's favorable profile and potential therapeutic benefit'",2017-10-05 08:31:00-04:00,SCYX,positive
1122255.0,"Scynexis CEO Buys 10,000 @ Avg Price: $1.61 -Form4",2017-08-17 09:37:00-04:00,SCYX,neutral
1122256.0,"SCYNEXIS Reports Q2 EPS $(0.16) vs $(0.31) Est., Slaes $64K vs $60K Est.",2017-08-08 16:43:00-04:00,SCYX,neutral
1122257.0,SCYNEXIS Reports Dosing Initiated In SCY-078 Phase 2 Study,2017-08-08 16:42:00-04:00,SCYX,neutral
1122258.0,SCYNEXIS Reports Initiation Of Dosing In Phase 2 Study Evaluating Oral SCY-078 In Vulvovaginal Candidiasis,2017-08-03 17:54:00-04:00,SCYX,neutral
1122259.0,SCYNEXIS Reports New Study Shows In Vitro Activity Of Co.'s SCY-078 Against Drug-Resistant Candida Fungal Strains,2017-06-15 08:34:00-04:00,SCYX,negative
1122260.0,SCYNEXIS Reports 'Multiple studies confirm high compatibility of SCY-078 with other antifungals and favorable safety profile',2017-06-05 08:36:00-04:00,SCYX,positive
1122261.0,SCYNEXIS Reports Potent In Vitro Activity Of SCY-078 In CDC Study,2017-05-11 08:34:00-04:00,SCYX,neutral
1122262.0,Mid-Afternoon Market Update: Crude Oil Down 1%; CPI Aerostructures Shares Spike Higher,2017-05-09 14:33:00-04:00,SCYX,negative
1122263.0,20 Biggest Mid-Day Losers For Tuesday,2017-05-09 12:32:00-04:00,SCYX,negative
1122264.0,Mid-Day Market Update: TravelCenters Drops After Q1 Results; Wayfair Shares Climb,2017-05-09 11:56:00-04:00,SCYX,positive
1122265.0,Mid-Morning Market Update: Markets Open Higher; Dean Foods Earnings Miss Views,2017-05-09 10:12:00-04:00,SCYX,negative
1122267.0,SCYNEXIS Reports Will Offer 8 Data Presentations at ECCMID Showcase: Presentations Will Support SCY-078's Potential as Novel Treatment for Candida Infections Including Multidrug-Resistant Strains,2017-04-25 09:05:00-04:00,SCYX,positive
1122268.0,18 Biggest Mid-Day Gainers For Monday,2017-04-24 13:29:00-04:00,SCYX,neutral
1122269.0,25 Stocks Moving In Monday's Pre-Market Session,2017-04-24 08:20:00-04:00,SCYX,neutral
1122270.0,"SCYNEXIS Reports FY16 EPS $(1.58) vs $(1.60) Est., Cash and Cash Equivalents, Short-Term Investments Totaled $58.6M as of Dec. 31, 2016",2017-03-13 16:32:00-04:00,SCYX,neutral
1122271.0,Mid-Afternoon Market Update: Immersion Drops After Q4 Results; Snap Shares Spike Higher,2017-03-03 14:36:00-05:00,SCYX,positive
1122272.0,15 Biggest Mid-Day Losers For Friday,2017-03-03 13:20:00-05:00,SCYX,negative
1122273.0,Mid-Day Market Update: Nutanix Drops On Weak Guidance; BioScrip Shares Climb,2017-03-03 12:23:00-05:00,SCYX,negative
1122274.0,Mid-Morning Market Update: Markets Edge Lower; Big Lots Profit Beats Estimates,2017-03-03 10:01:00-05:00,SCYX,positive
1122275.0,22 Stocks Moving In Friday's Pre-Market Session,2017-03-03 08:28:00-05:00,SCYX,neutral
1122276.0,SCYNEXIS Shares to Resume Trade at 4:35 p.m. EST,2017-03-02 16:23:00-05:00,SCYX,positive
1122277.0,SCYNEXIS Delays Start Of New Clinical Studies Using IV Formulation Of SCY-078 At FDA's Request,2017-03-02 16:12:00-05:00,SCYX,neutral
1122278.0,SCYNEXIS Shares Halted News Pending,2017-03-02 16:03:00-05:00,SCYX,positive
1122279.0,Aegis Initiating Coverage On Scynexis With Buy and $7 PT,2017-01-31 13:28:00-05:00,SCYX,neutral
1122280.0,25 Stocks Moving In Thursday's Pre-Market Session,2017-01-26 08:19:00-05:00,SCYX,neutral
1122281.0,"SCYNEXIS INC: Taglietti Marco (Director, Chief Executive Officer) Buys 25,000 @ Avg Price: $3.30 (Form4)",2016-12-22 07:17:00-05:00,SCYX,neutral
1122282.0,SCYNEXIS Achieves New Development Milestones Reinforcing the Versatility of SCY-078 in Treating Serious Fungal Infections,2016-12-13 08:05:00-05:00,SCYX,negative
1122283.0,Reminder: SCYNEXIS Phase 1 Data On SCY-078 Expected By End Of Day Nov. 30th,2016-11-29 17:02:00-05:00,SCYX,neutral
1122284.0,"SCYNEXIS Reports Q3 EPS $(0.48) vs. Est. $(0.50), Rev. $64k vs. Est. $70K",2016-11-07 16:41:00-05:00,SCYX,neutral
1122285.0,SCYNEXIS Completes Two Additional Clinical Studies Further Supporting the Favorable Safety Profile of SCY-078,2016-10-25 09:06:00-04:00,SCYX,positive
1122286.0,Benzinga's Top Initiations,2016-10-20 09:14:00-04:00,SCYX,positive
1122287.0,"H.C. Wainwright Initiates Coverage On SCYNEXIS, Inc. - Common Stock at Buy, Announces $14.00",2016-10-20 07:04:00-04:00,SCYX,neutral
1122288.0,WBB Securities Upgrades SCYNEXIS to Strong Buy,2016-10-07 08:34:00-04:00,SCYX,positive
1122289.0,12 Biggest Mid-Day Gainers For Thursday,2016-10-06 12:55:00-04:00,SCYX,neutral
1122290.0,Volatile Trading Seen In SCYNEXIS Amid Favorable Trial News,2016-10-06 10:11:00-04:00,SCYX,positive
1122291.0,18 Stocks Moving In Thursday's Pre-Market Session,2016-10-06 08:43:00-04:00,SCYX,neutral
1122292.0,"SCYNEXIS Reports Results Confirm Antifungal Activity Of Oral SCY-078, Well-Tolerated And Active Oral Dose",2016-10-05 16:18:00-04:00,SCYX,positive
1122293.0,"Brean Assumes SCYNEXIS Shares At Buy, Sees 300% Upside",2016-10-03 09:46:00-04:00,SCYX,positive
1122294.0,"Brean Capital Assumes SCYNEXIS at Buy, Announces $16.00 PT",2016-10-03 06:15:00-04:00,SCYX,neutral
1122295.0,"Bio Pharma Companies Expected To Report Data By Friday Sept. 30 Include Genocea Biosciences, SCYNEXIS, Threshold Pharmaceuticals, Arbutus Biopharma, Cytori Therapeutics, Esperion Therapeutics, Mesoblast, Marinus Pharmaceuticals, & Syndax Pharmaceuticals",2016-09-26 17:17:00-04:00,SCYX,neutral
1122296.0,30 Stocks With Three-Day Increasing Volume,2016-09-20 09:10:00-04:00,SCYX,neutral
1122297.0,15 Stocks Which Rallied Three Days On Increasing Volume,2016-09-20 08:58:00-04:00,SCYX,neutral
1122298.0,18 Biggest Mid-Day Gainers For Wednesday,2016-08-24 12:56:00-04:00,SCYX,neutral
1122299.0,SCYNEXIS Reports Orphan Drug Designation for SCY-078 for Treatment of Invasive Aspergillus Infections,2016-08-24 09:06:00-04:00,SCYX,neutral
1122300.0,14 Stocks Moving In Wednesday's Pre-Market Session,2016-08-24 08:28:00-04:00,SCYX,neutral
1122301.0,15 Biggest Mid-Day Gainers For Thursday,2016-08-18 13:49:00-04:00,SCYX,neutral
1122302.0,20 Stocks Moving In Thursday's Pre-Market Session,2016-08-18 08:40:00-04:00,SCYX,neutral
1122303.0,18 Biggest Mid-Day Gainers For Wednesday,2016-08-17 12:54:00-04:00,SCYX,neutral
1122304.0,Mid-Day Market Update: Urban Outfitters Surges Following Upbeat Results; 21Vianet Shares Slide,2016-08-17 12:16:00-04:00,SCYX,positive
1122305.0,Benzinga's Top Initiations,2016-08-17 09:30:00-04:00,SCYX,positive
1122306.0,20 Stocks Moving In Wednesday's Pre-Market Session,2016-08-17 08:18:00-04:00,SCYX,neutral
1122307.0,Guggenheim Securities Initiates Coverage on SCYNEXIS at Buy,2016-08-17 06:40:00-04:00,SCYX,positive
1122308.0,WBB Securities Upgrades SCYNEXIS to Buy,2016-08-09 09:21:00-04:00,SCYX,positive
1122309.0,"SCYNEXIS Reports Q2 EPS $(0.56) vs $(0.52) Est., Sales $64K vs $90K Est.",2016-08-08 09:06:00-04:00,SCYX,neutral
1122310.0,SCYNEXIS Oral SCY-078 Achieves Target Exposure With Favorable Safety And Tolerability in Patients with Invasive Candidiasis,2016-08-01 09:37:00-04:00,SCYX,positive
1122311.0,15 Stocks Moving In Monday's Pre-Market Session,2016-08-01 08:34:00-04:00,SCYX,neutral
1122312.0,"SCYNEXIS Announces Interim Results from Phase 2 Study of Oral SCY-078 in Patients with Invasive Candidiasis, Met All Primary Endpoints",2016-08-01 08:00:00-04:00,SCYX,neutral
1122313.0,"SCYNEXIS, Inc. Announces Sale of Cyclophilin Inhibitor Assets to Cypralis Limited, Terms Not Disclosed",2016-07-13 08:30:00-04:00,SCYX,negative
1122314.0,"CEO Taglietti Buys 100,000 Shares of Scynexis @$2.39/Share -Form 4",2016-06-28 07:56:00-04:00,SCYX,positive
1122315.0,8 Biggest Mid-Day Losers For Tuesday,2016-06-21 12:56:00-04:00,SCYX,negative
1122316.0,Mid-Day Market Update: Crude Oil Down 2%; American Science & Engineering Shares Surge On Acquisition News,2016-06-21 12:10:00-04:00,SCYX,negative
1122317.0,Mid-Morning Market Update: Markets Open Higher; CarMax Misses Q1 Estimates,2016-06-21 09:54:00-04:00,SCYX,negative
1122318.0,SCYNEXIS Prices 9.375M Share Offering at $2.40/Share,2016-06-21 09:16:00-04:00,SCYX,positive
1122319.0,12 Stocks Moving In Tuesday's Pre-Market Session,2016-06-21 08:18:00-04:00,SCYX,neutral
1122320.0,SCYNEXIS Reports Public Offering of Common Stock and Warrants,2016-06-20 16:02:00-04:00,SCYX,neutral
1122321.0,UPDATE: SCYNEXIS Says SCY-078 Has Shown 'to be the first glucan synthase inhibitor with high oral bioavailability in humans',2016-06-20 08:02:00-04:00,SCYX,negative
1122322.0,"SCYNEXIS Reports Presentation of New Clinical, Non-Clinical Data Showing SCY-078 Potential as Novel Treatment for Life-Threatening Fungal Infections",2016-06-20 08:01:00-04:00,SCYX,positive
1122323.0,11 Biggest Mid-Day Losers For Thursday,2016-06-09 12:52:00-04:00,SCYX,negative
1122324.0,Mid-Day Market Update: Restoration Hardware Falls Following Earnings Miss; Jaguar Animal Health Shares Jump,2016-06-09 12:15:00-04:00,SCYX,positive
1122325.0,"SCYNEXIS, Inc. Announces Positive Results in its Proof-of-Concept Phase 2 Study of SCY-078, the First Member of a Novel Class of Glucan Synthase Inhibitors",2016-06-08 16:05:00-04:00,SCYX,positive
1122326.0,SCYNEXIS Gets Orphan Drug Status For SCY-078,2016-05-13 10:03:00-04:00,SCYX,neutral
1122327.0,"SCYNEXIS, Inc. Receives Orphan Drug Designation for SCY-078 for the Treatment of Invasive Candida Infections",2016-05-13 08:00:00-04:00,SCYX,neutral
1122328.0,"SCYNEXIS Reports Q1 EPS $(0.52) vs. Est. $(0.63), Rev. $64K vs. Est. $100K",2016-05-09 09:26:00-04:00,SCYX,neutral
1122329.0,SCYNEXIS Gets SME Designation From European Medicines Agency,2016-04-19 10:19:00-04:00,SCYX,neutral
1122330.0,"SCYNEXIS Reports Received Designation as Small, Medium Enterprise by EMA",2016-04-19 09:16:00-04:00,SCYX,neutral
1122331.0,SCYNEXIS Offers Data Showing Support for Activity of SCY-078 Against Antifungal-Resistant Candida Strains,2016-04-15 09:01:00-04:00,SCYX,positive
1122332.0,Benzinga's Top Initiations,2016-03-28 10:05:00-04:00,SCYX,positive
1122333.0,"Brean Initiates SCYNEXIS With Buy Rating, $16 Price Target",2016-03-28 08:50:00-04:00,SCYX,neutral
1122334.0,"Brean Capital Initiates Coverage on SCYNEXIS at Buy, Announces $16.00 PT",2016-03-28 05:51:00-04:00,SCYX,neutral
1122335.0,"SCYNEXIS Says on March 16, 2016, Yves J. Ribeill, Ph.D. Announced he had Resigned from SCYNEXIS Board of Directors Effective Immediately",2016-03-21 08:22:00-04:00,SCYX,positive
1122336.0,Stocks Hitting 52-Week Lows,2016-03-14 10:06:00-04:00,SCYX,negative
1122337.0,Stocks Hitting 52-Week Lows,2016-03-07 10:27:00-05:00,SCYX,negative
1122338.0,"SCYNEXIS Reports FY15 EPS $(2.68) vs $(2.66) Est., Sales $257K vs $50K Est.",2016-03-07 08:38:00-05:00,SCYX,neutral
1122339.0,"SCYNEXIS, Inc. Receives FDA Fast Track and QIDP Designations for Intravenous Formulation of SCY-078 for the Treatment of Patients with Invasive Fungal Infections",2016-01-28 09:06:00-05:00,SCYX,neutral
1122340.0,12 Biotechs With Binary Events Coming This Year,2016-01-08 12:13:00-05:00,SCYX,neutral
1122341.0,Benzinga's Top Initiations,2015-12-30 10:02:00-05:00,SCYX,positive
1122342.0,Benzinga's Top Initiations,2015-12-29 11:32:00-05:00,SCYX,positive
1122343.0,"SCYNEXIS Shares Volatile, Rally ~11%; WBB Securities Earlier Started at Speculative Buy, $8 Target",2015-12-29 10:53:00-05:00,SCYX,positive
1122344.0,SCYNEXIS Reports Initiation of Enrollment in Phase 2 Study of SCY-078 in Vulvovaginal Candidiasis,2015-12-01 17:12:00-05:00,SCYX,neutral
1122345.0,Filing from Scynexis Shows Registration for $40M Common Stock Offering,2015-11-17 17:11:00-05:00,SCYX,neutral
1122346.0,SCYNEXIS Reports Q3 EPS ($0.60) vs. Est. ($0.62),2015-11-13 09:05:00-05:00,SCYX,neutral
1122347.0,"SCYNEXIS, Inc. Announces Initiation of Phase 1 Clinical Trial Evaluating Intravenous Formulation of SCY-078",2015-11-12 08:32:00-05:00,SCYX,neutral
1122348.0,SCYNEXIS Names Eric Francois as Chief Financial Officer,2015-11-02 17:26:00-05:00,SCYX,neutral
1122349.0,8-K from Scynexis Shows Co. Named Eric Francois as New CFO,2015-11-02 16:58:00-05:00,SCYX,neutral
1122350.0,"Scynexis Appoints Rajeshwar Motheram To Vice President, Pharmaceutical Development",2015-10-07 16:33:00-04:00,SCYX,neutral
1122351.0,"SCYNEXIS, Inc. Announces Board of Directors Transitions",2015-09-28 16:31:00-04:00,SCYX,neutral
1122352.0,SCYNEXIS Shows Data Supporting the Potential Clinical Utility of Antifungal Drug Candidate at ICAAC/ICC 2015,2015-09-21 08:31:00-04:00,SCYX,positive
1122353.0,"SCYNEXIS, Inc. to Focus on SCY-078 Development",2015-07-23 08:35:00-04:00,SCYX,neutral
1122354.0,"Needham Initiates Coverage on SCYNEXIS at Buy, Announces $16.00 PT",2015-06-10 08:13:00-04:00,SCYX,neutral
1122355.0,Broadfin Capital Initiates 5.6% Passive Stake In SCYNEXIS,2015-05-27 12:59:00-04:00,SCYX,positive
1122356.0,Morning Market Gainers,2015-04-23 09:46:00-04:00,SCYX,neutral
1122357.0,SCYNEXIS Prices ~4.675M Share Offering @$7.70/Share,2015-04-22 22:36:00-04:00,SCYX,positive
1122358.0,"Amended S-1 from Scynexis Shows Launch of Common Stock Offering, Net Proceeds ~$27M",2015-04-20 07:42:00-04:00,SCYX,neutral
1122359.0,"Scynexis S-! Shows Filing Of $30M Stock Offer Via RBC Capital, Canaccord, JMP and Needham",2015-04-09 17:03:00-04:00,SCYX,neutral
1122360.0,SCYNEXIS Trading Resumed,2015-03-26 13:20:00-04:00,SCYX,neutral
1122361.0,SCYNEXIS Trading Halted,2015-03-26 13:16:00-04:00,SCYX,neutral
1122362.0,"SCYNEXIS Names Marco Taglietti as CEO, Announces Chief Medical Officer Has Submitted Resgination",2015-02-06 07:15:00-05:00,SCYX,neutral
1122363.0,Scynexis Announces Fast Track Designation for SCY-078,2015-01-09 08:31:00-05:00,SCYX,neutral
1122364.0,"SCYNEXIS, Inc. Announces Appointment Of Two Seasoned Industry Professionals To Its Board of Directors",2014-12-03 08:32:00-05:00,SCYX,neutral
1122365.0,Scynexis Reports Q3 EPS of $(0.45) vs $(0.53) Est,2014-11-13 08:33:00-05:00,SCYX,neutral
1122366.0,SCYNEXIS Inc. Enters Into Worldwide Agreement With Waterstone Pharmaceutical ,2014-11-03 08:47:00-05:00,SCYX,positive
1122367.0,Scynexis Reports Q2 EPS of $(0.98) vs $(0.40) Est; Revenue of $4.64M vs $4.0M Est,2014-08-13 08:11:00-04:00,SCYX,neutral
1122368.0,SCYNEXIS Shares Spike Higher; Halted on Circuit Breaker,2014-08-07 10:58:00-04:00,SCYX,positive
1122369.0,Benzinga's Top Initiations,2014-06-02 07:53:00-04:00,SCYX,positive
1122370.0,"JMP Securities Initiates Coverage on Scynexis at Market Perform, Announces $15.00 PT",2014-06-02 06:47:00-04:00,SCYX,positive
1122371.0,"Canaccord Genuity Initiates Coverage on Scynexis at Buy, Announces $18.00 PT",2014-05-29 06:42:00-04:00,SCYX,neutral
1122372.0,"Canaccord Genuity Initiates Coverage on Scynexis at Buy, Announces $18.00 PT",2014-05-29 06:19:00-04:00,SCYX,neutral
1122373.0,"RBC Capital Initiates Coverage on Scynexis at Outperform, Announces $17.00 PT",2014-05-29 06:19:00-04:00,SCYX,neutral
1122374.0,"IPO Lookout For The Week Of May 5: Alder Biopharma, Cheetah Mobile, GasLog Partners",2014-05-05 09:45:00-04:00,SCYX,neutral
1122375.0,"Shares of SCYNEXIS Open for Trade Around $9.75/Share, Priced at $10",2014-05-02 11:20:00-04:00,SCYX,positive
1122377.0,"SCYNEXIS Reports Pricing of IPO, 6.2M Shares at $10/Share",2014-05-02 10:04:00-04:00,SCYX,positive
1122378.0,IPO Review For The Week Of April 7: IPOs Outperform S&P 500...Again,2014-04-12 16:05:00-04:00,SCYX,neutral
1122379.0,"IPO Outlook for Friday, April 11: City Office, Paycom Software, Farmland Partners & More",2014-04-11 07:45:00-04:00,SCYX,neutral
1122380.0,"IPO Lookout: IPOs For The Week Of April 7, 2014",2014-04-07 16:14:00-04:00,SCYX,neutral
1122381.0,IPO Lookout: IPOs for the Week of March 31,2014-03-31 16:37:00-04:00,SCYX,neutral
1122382.0,Scynexis Sees 4.2M Share IPO Priced $12.00-$14.00 -S-1/A,2014-03-19 06:31:00-04:00,SCYX,positive
